Tominersen for chorea

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Also followed for narrower conditions: Huntington Disease

Why this status

  1. 3 Dec 2018: Trial registered, NCT03761849
  2. 23 Jan 2019: Trial started, NCT03761849

The trials

NCT03761849: A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

State
Completed
Phase
Phase 3
People
899 taking part
Started
23 Jan 2019
Primary completion
24 Mar 2022
Arms
RO7234292 Q8W, RO7234292 Q16W
Results
Posted on the registry
  1. 3 Dec 2018: Trial registered
  2. 23 Jan 2019: Trial started
  3. 24 Mar 2022: Trial completed
  4. 7 Nov 2023: Trial results posted

NCT04000594: A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease

State
Completed
Phase
Phase 1
People
12 taking part
Started
2 Sep 2019
Primary completion
18 Jan 2022
Arms
Dose level 1 of RO7234292 (RG6042), Dose level 2 of RO7234292 (RG6042), Dose level 3 of RO7234292 (RG6042)
Results
Posted on the registry
  1. 27 Jun 2019: Trial registered
  2. 2 Sep 2019: Trial started
  3. 18 Jan 2022: Trial completed
  4. 3 Oct 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as ISIS 443139 10 mg, ISIS 443139 120 mg, ISIS 443139 30 mg, ISIS 443139 60 mg, ISIS 443139 90 mg, RO7234292, RO7234292 (RG6042).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.